WealthPlan Investment Management LLC Makes New Investment in Seelos Therapeutics, Inc. (NASDAQ:SEEL)

WealthPlan Investment Management LLC acquired a new position in shares of Seelos Therapeutics, Inc. (NASDAQ:SEEL – Get Rating) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 80,786 shares of the company’s stock, valued at approximately $86,000.

Several other institutional investors have also recently bought and sold shares of the business. Citigroup Inc. raised its holdings in shares of Seelos Therapeutics by 113.3% in the first quarter. Citigroup Inc. now owns 53,533 shares of the company’s stock valued at $45,000 after purchasing an additional 28,431 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Seelos Therapeutics by 9.8% in the first quarter. Vanguard Group Inc. now owns 5,650,988 shares of the company’s stock valued at $4,735,000 after purchasing an additional 504,505 shares during the last quarter. Penserra Capital Management LLC raised its holdings in shares of Seelos Therapeutics by 16.7% in the first quarter. Penserra Capital Management LLC now owns 373,497 shares of the company’s stock valued at $235,000 after purchasing an additional 53,429 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Seelos Therapeutics by 7.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 264,684 shares of the company’s stock valued at $222,000 after purchasing an additional 19,005 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Seelos Therapeutics in the first quarter valued at about $1,438,000. Institutional investors and hedge funds own 25.39% of the company’s stock.

Seelos Therapeutics Stock Performance

Shares of SEEL stock opened at $0.66 on Friday. The firm has a 50-day moving average of $0.78 and a 200-day moving average of $0.90. The company has a market cap of $71.63 million, a P/E ratio of -0.84 and a beta of 1.88. The company has a debt-to-equity ratio of 1.36, a current ratio of 0.90 and a quick ratio of 1.85. Seelos Therapeutics, Inc. has a one year low of $0.48 and a one year high of $1.52.

Seelos Therapeutics Company Profile

(Get Rating)

Seelos Therapeutics, Inc is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm’s portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder �or Post-Traumatic Stress Disorder, �amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson’s disease, other psychiatric and movement disorders plus orphan diseases.